EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries

Christian Récher iD, Pierre-Yves Dumas, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Jean Galtier iD, Camille Alric, Audrey Bidet iD, Eric Delabesse, Jean Baptiste Rieu iD, Jean-Philippe Vial, François Vergez iD und 13 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Christian Récher und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Université Toulouse III Paul Sabatier, Toulouse,…. Hauptthemen laut MEDLINE: Cytarabine, Leukemia, Myeloid, Acute, Remission Induction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate‐dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini‐consolidations (idarubicin 8 mg/m 2 day 1, cytarabine 50 mg/m 2 /12 h, day 1–5) and IDAC. Inclusion criteria were newly diagnosed AML, age > 60 years, first CR after induction and at least 1 cycle of consolidation. Of the 796 included patients, 322 patients received mini‐consolidations and 474 patients received IDAC. Mini‐consolidation patients were older, and more often, they had de novo AML and unfavorable risk. The rate of allogeneic transplantation was higher in the IDAC group. The median number of cycles was higher in the mini‐consolidation group (4 vs. 2; p < .0001). Median relapse‐free survival was 18 months with mini‐consolidations and 12 months with IDAC ( p = .0064). In multivariate analysis, the risk of relapse or death was significantly higher in the IDAC group ( p = .004). Median OS was 36 versus 31 months with mini‐consolidations or IDAC, respectively ( p = .46). In multivariate analysis, the consolidation regimen had no significant influence on OS ( p = .43). In older AML patients, post‐remission therapy with mini‐consolidations represents an alternative to IDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytarabineLeukemia, Myeloid, AcuteRemission InductionHumansMiddle AgedRetrospective StudiesAgedMaleFemaleRegistriesConsolidation ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalIdarubicinAntimetabolites, AntineoplasticAged, 80 and over

Substanzen

CytarabineIdarubicinAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Institut National de la Santé et de la Recherche Médicale, U1312, Service d'Hématologie Clinique et de Thérapie Cellulaire, Université de Bordeaux, CHU Bordeaux, Bordeaux, France.
  • Service d'Epidémiologie, CERPOP, Inserm, Centre Hospitalier Universitaire de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Laboratoire d'Hématologie Biologique, CHU Bordeaux, Bordeaux, France.
  • Laboratoire d'Hématologie Biologique, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  • Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Dresden, Germany.

ORCID-Profile: Christian Récher, Jean Galtier, Audrey Bidet, Jean Baptiste Rieu, François Vergez, Emilie Klein, Sven Zukunft, Sarah Bertoli

Zitieren

APA

Récher, C., Dumas, P. Y., Bérard, E., Tavitian, S., Leguay, T., Galtier, J., Alric, C., Bidet, A., Delabesse, E., Rieu, J. B., Vial, J. P., Vergez, F., Luquet, I., Klein, E., de Grande, A. C., Sarry, A., Zukunft, S., Platzbecker, U., Müller-Tidow, C., …, & Röllig, C. (2025). Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries. American Journal of Hematology. https://doi.org/10.1002/ajh.27510

Vancouver

Récher C, Dumas PY, Bérard E, Tavitian S, Leguay T, Galtier J, et al. Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries. American Journal of Hematology. 2025. doi:10.1002/ajh.27510

BibTeX
@article{Rcher2025,
  author = {Récher, Christian and Dumas, Pierre-Yves and Bérard, Emilie and Tavitian, Suzanne and Leguay, Thibaut and Galtier, Jean and Alric, Camille and Bidet, Audrey and Delabesse, Eric and Rieu, Jean Baptiste and Vial, Jean-Philippe and Vergez, François and Luquet, Isabelle and Klein, Emilie and de Grande, Anne-Charlotte and Sarry, Audrey and Zukunft, Sven and Platzbecker, Uwe and Müller-Tidow, Carsten and Baldus, Claudia D and Bornhäuser, Martin and Serve, Hubert and Bertoli, Sarah and Pigneux, Arnaud and Röllig, Christoph},
  title = {Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27510}
}
Kostenlos starten →